As of 2026-03-30, the Intrinsic Value of Atara Biotherapeutics Inc (ATRA) is 1.15 USD. This Atara valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 4.59 USD, the upside of Atara Biotherapeutics Inc is -74.90%.
The range of the Intrinsic Value is (5.62) - 257.69 USD
Based on its market price of 4.59 USD and our intrinsic valuation, Atara Biotherapeutics Inc (ATRA) is overvalued by 74.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (5.62) - 257.69 | 1.15 | -74.9% |
| DCF (Growth 10y) | 19.10 - 3,157.12 | 79.66 | 1635.5% |
| DCF (EBITDA 5y) | 74.08 - 276.06 | 140.76 | 2966.7% |
| DCF (EBITDA 10y) | 89.72 - 777.93 | 254.87 | 5452.6% |
| Fair Value | 89.58 - 89.58 | 89.58 | 1,851.67% |
| P/E | 73.67 - 101.22 | 86.51 | 1784.7% |
| EV/EBITDA | 80.51 - 110.54 | 93.95 | 1946.9% |
| EPV | (51.22) - (236.51) | (143.86) | -3234.3% |
| DDM - Stable | 39.10 - 189.81 | 114.46 | 2393.7% |
| DDM - Multi | 151.43 - 587.17 | 242.68 | 5187.1% |
| Market Cap (mil) | 41.87 |
| Beta | 1.06 |
| Outstanding shares (mil) | 9.12 |
| Enterprise Value (mil) | 75.81 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.06% |
| Cost of Debt | 25.03% |
| WACC | 16.48% |